Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

ILMN

Illumina Inc

Feb 11 • 04:00PM ET

116.38

-2.94 -2.46 %

Healthcare • Diagnostics & Research • USA • NASD

Feb 06, 8:30 PMDisappointing 2026 revenue guidance sparked a sharp sell-off despite Q4 earnings beat.

Peers: PACB VRTX TXG QGEN GH BIO MYGN IONS TWST OMIC

| Held by: VTI IJH VB VBR VXF XMHQ MDY IBB SPMD ARKK

Index	-	P/E	21.34	EPS (ttm)	5.45	Insider Own	2.81%	Shs Outstand	152.80M	Perf Week	-13.27%
Market Cap	17.78B	Forward P/E	19.99	EPS next Y	5.82	Insider Trans	-0.00%	Shs Float	148.51M	Perf Month	-20.04%
Enterprise Value	18.62B	PEG	1.82	EPS next Q	1.07	Inst Own	104.74%	Short Float	5.59%	Perf Quarter	-4.39%
Income	850.00M	P/S	4.10	EPS this Y	5.66%	Inst Trans	1.49%	Short Ratio	4.40	Perf Half Y	19.51%
Sales	4.34B	P/B	7.48	EPS next Y	13.82%	ROA	13.13%	Short Interest	8.30M	Perf YTD	-11.27%
Book/sh	15.56	P/C	10.89	EPS next 5Y	10.98%	ROE	33.36%	52W High	155.53 -25.17%	Perf Year	15.59%
Cash/sh	10.69	P/FCF	17.78	EPS past 3/5Y	- 4.22%	ROIC	18.09%	52W Low	68.70 69.40%	Perf 3Y	-39.08%
Dividend Est.	-	EV/EBITDA	16.00	Sales past 3/5Y	-1.78% 6.04%	Gross Margin	67.07%	Volatility	4.19% 4.12%	Perf 5Y	-73.46%
Dividend TTM	-	EV/Sales	4.29	EPS Y/Y TTM	171.36%	Oper. Margin	20.58%	ATR (14)	5.58	Perf 10Y	-13.51%
Dividend Ex-Date	-	Quick Ratio	1.72	Sales Y/Y TTM	-0.73%	Profit Margin	19.59%	RSI (14)	27.87	Recom	2.46
Dividend Gr. 3/5Y	- -	Current Ratio	2.08	EPS Q/Q	84.80%	SMA20	-16.91%	Beta	1.47	Target Price	135.32
Payout	0.00%	Debt/Eq	0.91	Sales Q/Q	4.98%	SMA50	-15.23%	Rel Volume	1.08	Prev Close	119.32
Employees	10370	LT Debt/Eq	0.73	Earnings	Feb 05 AMC	SMA200	8.27%	Avg Volume	1.89M	Price	116.38
IPO	Jul 28, 2000	Option/Short	Yes / Yes	EPS/Sales Surpr.	8.70% 3.60%	Trades		Volume	2,032,567	Change	-2.46%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-12-25	Downgrade	Daiwa Securities	Outperform → Neutral	$94
Jul-11-25	Downgrade	Scotiabank	Sector Outperform → Sector Perform	$125
Mar-04-25	Reiterated	Citigroup	Neutral	$130 → $90
Feb-28-25	Downgrade	HSBC Securities	Buy → Hold	$100
Feb-10-25	Downgrade	Barclays	Equal Weight → Underweight	$130 → $100
Feb-07-25	Downgrade	TD Cowen	Buy → Hold	$177 → $140
Dec-11-24	Downgrade	Citigroup	Buy → Neutral	$190 → $165
Nov-12-24	Resumed	Morgan Stanley	Equal-Weight	$156
Oct-17-24	Upgrade	HSBC Securities	Hold → Buy	$180
Aug-28-24	Upgrade	Argus	Hold → Buy
Aug-16-24	Upgrade	Daiwa Securities	Neutral → Buy	$120 → $154
Aug-14-24	Upgrade	TD Cowen	Hold → Buy	$126 → $144
Aug-14-24	Upgrade	Barclays	Underweight → Equal Weight	$125
Jul-10-24	Upgrade	Citigroup	Neutral → Buy	$140
Jun-03-24	Resumed	Jefferies	Hold	$115
Jan-16-24	Downgrade	HSBC Securities	Buy → Hold
Jan-04-24	Downgrade	TD Cowen	Outperform → Market Perform	$144
Dec-18-23	Upgrade	Scotiabank	Sector Perform → Sector Outperform	$185
Dec-15-23	Upgrade	Bernstein	Underperform → Mkt Perform
Dec-14-23	Initiated	Stephens	Overweight	$170

Show Previous Ratings

Feb-09-26 11:19AM	Waters Q4 Earnings Call Highlights (MarketBeat)
09:15AM	Unlocking Illumina (ILMN) International Revenues: Trends, Surprises, and Prospects (Zacks)
Feb-06-26 01:25PM	Tech Bounces As Software Sell-Off Eases, Dow Jones Hits Records: What's Moving Markets Friday? (Benzinga) -10.40%
03:48AM	Analyst Report: Illumina, Inc. (Morningstar Research)
12:36AM	ILMN Q4 Deep Dive: Clinical Consumables Growth, Multiomics Expansion, and Margin Momentum (StockStory)
12:05AM	Loading…
12:05AM	Illumina Inc (ILMN) Q4 2025 Earnings Call Highlights: Strong Clinical Growth Amidst Research ... (GuruFocus.com)
Feb-05-26 08:58PM	Illumina Q4 Earnings Call Highlights (MarketBeat)
07:00PM	Illumina (ILMN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
06:00PM	Illumina (ILMN) Tops Q4 Earnings and Revenue Estimates (Zacks)
04:59PM	Illumina: Q4 Earnings Snapshot (Associated Press Finance)
04:17PM	Illumina (NASDAQ:ILMN) Reports Bullish Q4 CY2025 (StockStory)
04:06PM	Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2025 (PR Newswire)
Feb-04-26 09:15AM	Insights Into Illumina (ILMN) Q4: Wall Street Projections for Key Metrics (Zacks)
Feb-03-26 10:18PM	Illumina (ILMN) Reports Q4: Everything You Need To Know Ahead Of Earnings (StockStory)
06:15PM	Aytu BioPharma Inc. (AYTU) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
09:15AM	Loading…
09:15AM	Illumina and the San Diego Zoo Wildlife Alliance partner to sequence the Frozen Zoo, supporting critical conservation genetics efforts globally (PR Newswire)
08:55AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
Feb-02-26 09:37AM	ILMN Q4 Earnings Preview: NovaSeq X Momentum Likely to Aid Performance (Zacks)
12:47AM	Grail files for FDA approval of multi-cancer early detection test (MedTech Dive)
Jan-30-26 10:00AM	Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for (Zacks)
09:05AM	Illumina completes acquisition of SomaLogic (PR Newswire)
Jan-29-26 10:00AM	Illumina (ILMN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Jan-27-26 08:55AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
Jan-24-26 12:01PM	The Most Expensive Question Investors Ask (Barchart)
Jan-23-26 11:40AM	REGN or ILMN: Which Is the Better Value Stock Right Now? (Zacks)
Jan-21-26 10:31PM	Life Sciences Tools & Services Stocks Q3 Teardown: Illumina (NASDAQ:ILMN) Vs The Rest (StockStory)
04:58PM	Cathie Wood Has 13 Big Ideas For 2026: Here's The Ark Invest List And Stocks To Watch (Benzinga)
Jan-20-26 01:19PM	Illumina Gets Medicare Boost for Cancer Test, Shares Climb (Benzinga)
09:15AM	Illumina secures CMS reimbursement for TruSight Oncology Comprehensive, expanding access to precision oncology (PR Newswire)
04:58AM	Illumina Inc. (ILMN) Shares See Target Boost as Analysts See Potential 2026 Upside (Insider Monkey)
12:05AM	Loading…
12:05AM	Cathie Wood's Ark Unleashes Cryptic ARKmoji Teasers To Showcase Its 'Big Ideas' For 2026: Can You Take A Guess At The Hidden Meaning? (Benzinga)
Jan-16-26 02:22AM	The clinical candidates pharma execs are tracking (Pharma Voice)
Jan-15-26 08:55AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
Jan-13-26 04:58PM	Illumina CEO Sees Big Growth Opportunity in China (Bloomberg)
01:01PM	JPM26: Illumina debuts Billion Cell Atlas to drive AI-driven drug discovery (Pharmaceutical Technology)
12:37PM	Analyst Report: Illumina, Inc. (Morningstar Research)
09:15AM	Illumina introduces Billion Cell Atlas to accelerate AI and drug discovery (PR Newswire)
09:00AM	Illumina Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2025 (PR Newswire)
07:30AM	TEM's Collab for Oncology Patient Population Is Gaining Attention (Zacks)
Jan-12-26 04:07PM	Illumina to Announce Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 5, 2026 (PR Newswire)
11:34AM	Nvidia, Eli Lilly announce $1 billion investment in AI drug discovery lab (Yahoo Finance)
08:09AM	Illumina's New Connected Multiomics Platform Set to Boost Its Stock (Zacks)
Jan-09-26 12:10PM	Will Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report? (Zacks)
08:55AM	How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings (Zacks)
Jan-08-26 04:30PM	Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026 (Business Wire)
04:30PM	Illumina Appoints Dr. Eric Green as Chief Medical Officer (PR Newswire)
Jan-07-26 11:40AM	REGN vs. ILMN: Which Stock Is the Better Value Option? (Zacks)
07:33AM	TEM's Stable Solvency and Financial Strength Are Gaining Attention (Zacks)
Jan-06-26 07:48PM	Analyst Report: Illumina, Inc. (Morningstar Research)
11:40AM	REGN vs. ILMN: Which Stock Should Value Investors Buy Now? (Zacks)
09:15AM	Illumina launches powerful software for connected, intuitive, and scalable multiomic analysis (PR Newswire)
07:06AM	Three Genomics Stocks Worth Tracking This Year (Zacks)
Jan-02-26 07:35AM	Is This the Right Time to Add PBH Stock to Your Portfolio? (Zacks)
Dec-31-25 09:50AM	Here's Why Illumina (ILMN) is a Strong Momentum Stock (Zacks)
01:30AM	It's Earnings Warning Season. How to Profit From Others' Misery. (Barrons.com)
Dec-30-25 08:06AM	Should Myriad Genetics Stock Stay in Your Portfolio Right Now? (Zacks)
07:32AM	Should You Continue to Hold EXAS Stock in Your Portfolio Now? (Zacks)
Dec-26-25 07:49AM	Should You Continue to Hold BRKR Stock in Your Portfolio? (Zacks)
07:18AM	How Tempus AI Is Advancing Toward Regulatory Pricing Catch-Up (Zacks)
07:17AM	Reasons to Retain Penumbra Stock in Your Portfolio for Now (Zacks)
Dec-24-25 08:36AM	Is Quest Diagnostics Stock a Right Pick for Your Portfolio Now? (Zacks)
Dec-23-25 02:08PM	Is This the Right Time to Add Veracyte Stock to Your Portfolio? (Zacks)
02:08PM	Abbott Stock May Benefit Following Volt PFA's FDA Approval (Zacks)
Dec-22-25 07:49AM	TMO Stock May Benefit From PPD CorEvitas Alzheimer's Registry Launch (Zacks)
07:11AM	Illumina (ILMN) Surges 3.3%: Is This an Indication of Further Gains? (Zacks)
Dec-19-25 09:09AM	National Vision Stock Surges 154.6% in a Year: What's Driving it? (Zacks)
Dec-18-25 08:36AM	Should You Continue to Hold CRL Stock in Your Portfolio for Now? (Zacks)
07:45AM	Should Investors Hold Chemed Stock in Their Portfolio Now? (Zacks)
Dec-17-25 10:14AM	Can These 5 Relative Price Strength Stocks Lead in 2026? (Zacks)
07:58AM	How the OneStep Partnership Could Drive Growth for ZBH Stock (Zacks)
07:55AM	Should You Retain Teleflex Stock in Your Portfolio Now? (Zacks)
Dec-16-25 04:05PM	Illumina To Webcast Upcoming Investor Conference (PR Newswire)
07:58AM	Is Phibro Animal Health Stock a Smart Addition to Your Portfolio Now? (Zacks)
07:47AM	TMO Stock Set to Gain From the Expansion of Gibco Bacto Portfolio (Zacks)
Dec-15-25 09:12AM	CVS Stock Gains From Offering MMR Vaccine to South Carolina Residents (Zacks)
Dec-12-25 09:50AM	Why Illumina (ILMN) is a Top Momentum Stock for the Long-Term (Zacks)
07:11AM	Is it Apt to Retain Haemonetics Stock in Your Portfolio Now? (Zacks)
Dec-11-25 09:15AM	Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually (PR Newswire)
08:09AM	Should You Continue to Hold EW Stock in Your Portfolio? (Zacks)
Dec-10-25 08:34AM	Is it Worth Retaining NEOG Stock in Your Portfolio for Now? (Zacks)
08:31AM	Phibro Animal Health Stock Climbs 59.6% YTD: What's Driving It? (Zacks)
Dec-09-25 07:28AM	ALGN Stock Rises on Thailand Launch of Invisalign With MAOB (Zacks)
07:27AM	Reasons to Hold Tandem Diabetes Stock in Your Portfolio for Now (Zacks)
07:26AM	RMD Stock Set to Gain From FDA Clearance of AI-Enabled Smart Comfort (Zacks)
04:49AM	Zacks.com featured highlights include Illumina, Commercial Metals and Newmont (Zacks)
Dec-08-25 10:15AM	Tempus AI: Data Flywheel and MRD Expansion Reshape the Outlook (Zacks)
09:45AM	Bet on These 3 Stocks With Upgraded Broker Ratings Amid Uncertainties (Zacks)
07:56AM	PODD Stock Benefits From FDA Approval of Omnipod 5's Enhancements (Zacks)
Dec-05-25 11:30AM	Why Is Acadia (ACAD) Up 22.6% Since Last Earnings Report? (Zacks)
08:48AM	MDT Stock Set to Benefit From the FDA Clearance of Hugo RAS System (Zacks)
Dec-04-25 11:30AM	Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue? (Zacks)
07:20AM	New Strong Buy Stocks for December 4th (Zacks)
Dec-03-25 12:00PM	Illumina (ILMN) Moves to Strong Buy: Rationale Behind the Upgrade (Zacks)
Nov-20-25 04:15PM	Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth (Business Wire)
05:00AM	Roche inks deal for rights to Freenome cancer tests outside US (MedTech Dive)
Nov-19-25 09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Nov-18-25 11:01PM	3 Reasons to Sell ILMN and 1 Stock to Buy Instead (StockStory)
08:48AM	Top 3 Genomics Stocks to Consider for Your Portfolio (Zacks)
Nov-12-25 12:00PM	Illumina whole-genome sequencing provides greater insight into genetic signals behind common diseases--according to Nature study (PR Newswire)
Nov-11-25 04:05PM	Illumina To Webcast Upcoming Investor Conference (PR Newswire)

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gottlieb Scott	Director	Feb 09 '26	Buy	117.81	200	23,562	12,723	Feb 11 04:04 PM
Davies Scott M	Chief Legal Officer	Dec 12 '25	Sale	136.09	323	43,957	17,887	Dec 16 05:00 PM
SCOTT DAVIES	Officer	Dec 12 '25	Proposed Sale	136.09	323	43,957		Dec 12 04:09 PM
Wedel Christensen Jakob	SVP, Strategy/Corp Development	Dec 08 '25	Sale	129.27	549	70,969	10,952	Dec 09 04:15 PM
JAKOB WEDEL	Officer	Dec 08 '25	Proposed Sale	129.27	549	70,969		Dec 08 04:31 PM
ILLUMINA, INC.	10% Owner	Nov 17 '25	Sale	79.85	1,000,000	79,850,000	3,502,126	Nov 18 09:33 PM
SCOTT DAVIES	Officer	Nov 12 '25	Proposed Sale	122.79	323	39,661		Nov 12 04:05 PM
Gottlieb Scott	Director	Nov 03 '25	Buy	122.13	500	61,065	12,523	Nov 05 04:05 PM
Dhingra Ankur	SVP, Chief Financial Officer	May 12 '25	Buy	81.21	6,100	495,381	24,906	May 14 04:20 PM
Thaysen Jacob	Chief Executive Officer	May 12 '25	Buy	80.88	6,500	525,732	77,540	May 14 04:18 PM
Thaysen Jacob	Chief Executive Officer	May 13 '25	Buy	80.84	5,850	472,942	83,390	May 14 04:18 PM
JAKOB WEDEL CHRISTENSEN	Officer	May 06 '25	Proposed Sale	77.21	549	42,388		May 06 04:02 PM
ARNOLD FRANCES	Director	Feb 27 '25	Proposed Sale	93.48	120	11,218		Feb 27 11:07 AM
JAKOB WEDEL	Officer	Feb 18 '25	Proposed Sale	100.00	460	46,000		Feb 18 04:22 PM
PATRICIA L LECKMAN	Officer	Feb 18 '25	Proposed Sale	100.00	1,756	175,600		Feb 18 04:08 PM

Open in Screener

TEM

Tempus AI Inc

Feb 11 • 04:00PM ET

53.61

-2.27 -4.06 %

Healthcare • Health Information Services • USA • NASD

Peers: ILMN EXAS GH TXG CRSP PACB NTLA EDIT CDNA TWST

| Held by: ARKK VTI VB ARKG VBK VXF BAI IBB IWP JTEK

Index	-	P/E	-	EPS (ttm)	-1.18	Insider Own	41.52%	Shs Outstand	172.63M	Perf Week	0.11%
Market Cap	9.54B	Forward P/E	-	EPS next Y	-0.23	Insider Trans	-2.51%	Shs Float	104.05M	Perf Month	-22.60%
Enterprise Value	10.11B	PEG	-	EPS next Q	-0.04	Inst Own	53.10%	Short Float	20.70%	Perf Quarter	-25.31%
Income	-203.88M	P/S	8.63	EPS this Y	61.78%	Inst Trans	22.09%	Short Ratio	4.43	Perf Half Y	-19.19%
Sales	1.11B	P/B	18.76	EPS next Y	62.41%	ROA	-12.53%	Short Interest	21.54M	Perf YTD	-9.21%
Book/sh	2.86	P/C	12.56	EPS next 5Y	-	ROE	-72.61%	52W High	104.32 -48.61%	Perf Year	-24.72%
Cash/sh	4.27	P/FCF	-	EPS past 3/5Y	-37.97% -32.48%	ROIC	-11.13%	52W Low	36.22 48.01%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	39.06% 38.58%	Gross Margin	60.33%	Volatility	6.19% 6.11%	Perf 5Y	-
Dividend TTM	-	EV/Sales	9.15	EPS Y/Y TTM	76.81%	Oper. Margin	-21.07%	ATR (14)	3.71	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.12	Sales Y/Y TTM	72.58%	Profit Margin	-18.45%	RSI (14)	34.91	Recom	1.88
Dividend Gr. 3/5Y	- -	Current Ratio	3.28	EPS Q/Q	0.15%	SMA20	-13.44%	Beta	5.28	Target Price	87.92
Payout	-	Debt/Eq	2.63	Sales Q/Q	84.72%	SMA50	-18.55%	Rel Volume	0.88	Prev Close	55.88
Employees	2400	LT Debt/Eq	2.61	Earnings	Feb 24 AMC	SMA200	-23.53%	Avg Volume	4.86M	Price	53.61
IPO	Jun 14, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	36.16% 1.67%	Trades		Volume	4,266,500	Change	-4.06%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-02-25	Resumed	Morgan Stanley	Overweight	$85
Oct-21-25	Downgrade	TD Cowen	Buy → Hold	$88
Oct-20-25	Initiated	Canaccord Genuity	Buy	$110
Sep-02-25	Initiated	H.C. Wainwright	Buy	$90
Apr-21-25	Initiated	BTIG Research	Buy	$60
Feb-25-25	Downgrade	JP Morgan	Overweight → Neutral	$50 → $55
Feb-12-25	Downgrade	William Blair	Outperform → Mkt Perform
Feb-05-25	Resumed	TD Cowen	Buy	$58 → $74
Dec-13-24	Initiated	Wolfe Research	Outperform	$60
Dec-09-24	Initiated	Guggenheim	Buy	$74
Nov-11-24	Downgrade	Stifel	Buy → Hold	$45 → $65
Oct-02-24	Downgrade	BofA Securities	Buy → Neutral	$45 → $60
Aug-12-24	Initiated	Piper Sandler	Neutral	$40
Jul-09-24	Initiated	William Blair	Outperform
Jul-09-24	Initiated	TD Cowen	Buy	$50
Jul-09-24	Initiated	Stifel	Buy	$45
Jul-09-24	Initiated	Needham	Buy	$47
Jul-09-24	Initiated	Morgan Stanley	Overweight	$44
Jul-09-24	Initiated	Loop Capital	Buy	$48
Jul-09-24	Initiated	Longbow	Buy	$48

Show Previous Ratings

Feb-11-26 11:13AM	HIMS Dips 55.8% in 3 Months: Should You Still Hold the Stock or Sell? (Zacks)
Feb-10-26 09:54AM	Jim Cramer on Tempus (TEM): "It's Going to Go Back Down Again" (Insider Monkey)
08:30AM	Tempus to Report Fourth Quarter and Full Year 2025 Financial Results on February 24 (Business Wire)
Feb-04-26 10:17PM	Tempus AI, Inc. (TEM): A Bull Case Theory (Insider Monkey)
07:00AM	Ambry's Contributions to MAVEs Support Thousands of Patient Reclassifications and Expand to New Genes (Business Wire)
07:00AM	Loading…
Feb-02-26 07:00AM	Ambry Genetics Announces One Millionth Test Leveraging RNA to Improve Diagnostic Accuracy and Yield (Business Wire)
Feb-01-26 06:50PM	Here Are Congresswoman Nancy Pelosi's Initial Stock Moves in 2026: They Include Nvidia, Alphabet, and Amazon Stocks, and Others (Motley Fool)
08:30AM	Tempus AI, Inc. (TEM) Strengthens Precision Medicine with New Tools, Partnerships, and Growth Milestones (Insider Monkey)
Jan-29-26 09:25AM	AI-Native Data Core Triggers Multi-Trillion Dollar Healthcare Structural Shift (PR Newswire)
08:47AM	TEM vs. DOCS: Which Medical-Tech Stock Looks Promising Amid AI Boom? (Zacks)
Jan-27-26 11:09AM	Nancy Pelosi Just Doubled Down on AI Again (24/7 Wall St.)
08:30AM	Tempus Reveals Its AI-Driven IPS Test More Accurately Predicts Immunotherapy Benefit Compared to Conventional Biomarkers (Business Wire)
Jan-26-26 08:56PM	Cathie Wood Bets Big On AI Trifecta: Ark Deploys $1.4 Million Across Medical, Autonomous Driving Sectors (Benzinga)
06:18PM	Pelosi's Bullish 2026 Buy List: AI, Power & Dividends (MarketBeat)
02:21PM	Nancy Pelosi Discloses New Stock Trades: Here's What She's Loading Up On - And What's She's Selling (Benzinga)
01:26PM	Loading…
01:26PM	Natural Gas Rallies 30%, Silver Jumps 13% To $116: What's Moving Markets Monday? (Benzinga)
10:20AM	Hims & Hers Scales Platform-Led Digital Healthcare Access and Care (Zacks)
09:40AM	How TEM Is Capitalizing on AI-Driven Pathology Market Growth (Zacks)
Jan-22-26 09:06PM	Cathie Wood Loads Up On This Robotaxi Stock, Ark Dumps Roku In Latest Trades (Benzinga)
12:42PM	HIMS vs. TEM: Which Health-Tech Stock Looks More Compelling? (Zacks)
10:10AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool)
Jan-21-26 09:06PM	Cathie Wood Doubles Down On Netflix Despite Weak Guidance, Ark Invest Dumps This Social Media Stock (Benzinga)
04:58PM	Cathie Wood Has 13 Big Ideas For 2026: Here's The Ark Invest List And Stocks To Watch (Benzinga)
08:30AM	Tempus Announces the Launch of Paige Predict (Business Wire)
07:57AM	Tempus AI's Key 2025 Milestones Continue to Gain Industry Attention (Zacks)
Jan-20-26 12:05AM	Cathie Wood's Ark Unleashes Cryptic ARKmoji Teasers To Showcase Its 'Big Ideas' For 2026: Can You Take A Guess At The Hidden Meaning? (Benzinga) -5.05%
Jan-13-26 07:48AM	Tempus AI (TEM) Soars 15% on $1.1-Billion Deal (Insider Monkey)
07:30AM	TEM's Collab for Oncology Patient Population Is Gaining Attention (Zacks)
Jan-12-26 07:27PM	Why Tempus AI Stock Rose Today (Motley Fool)
04:18PM	JPM Preannouncements: Why Alnylam And Sarepta Lost, But Day One Won (Investor's Business Daily)
02:53PM	Loading…
02:53PM	Why Tempus AI Stock Is Trading Higher On Monday? (Benzinga)
01:35PM	Why Tempus AI Stock Jumped on Monday? (GuruFocus.com)
01:08PM	Tempus AI's Pharma Momentum Accelerates (GuruFocus.com)
12:43PM	Gold, Silver Spike To Record Highs As Fed Independence Falters: What's Moving Markets Monday? (Benzinga)
10:58AM	Nancy Pelosi's Latest Trades Are Heating Up - Tempus AI's 100% Stock Surge Is Leading The Charge (Benzinga)
10:56AM	JPM Preannouncements Take Their Toll As Alnylam Slides, Tempus, Day One Pop (Investor's Business Daily)
08:30AM	Tempus and NYU Langone Health Announce Strategic Collaboration to Advance Precision Oncology (Business Wire)
07:51AM	Tempus AI Stock Rallies 105% in a Year: Should Investors Still Hold? (Zacks)
07:00AM	Northwestern Medicine Selects Tempus to Expand Genomic Testing (Business Wire)
05:47AM	Tempus AI Stock Soars After Posting Triple-Digit Diagnostics Growth (Benzinga)
05:33AM	Stock Market Today: Dow Jones, S&P 500 Futures Tumble As DOJ Serves Federal Reserve-Vistra, Tempus AI, Alibaba In Focus (Benzinga)
Jan-11-26 05:30PM	Tempus Achieves Record Total Contract Value Exceeding $1.1 Billion (Business Wire)
05:00PM	Tempus Announces Preliminary Fourth Quarter and Full Year 2025 Results (Business Wire)
Jan-09-26 07:45AM	Tempus AI Stock Surges 82.4% in a Year: What's Driving It? (Zacks)
Jan-08-26 06:18PM	Inverse Cramer Wins Again: Opposite Picks Of Investor Beat Nancy Pelosi In 2025 (Benzinga)
08:30AM	Tempus Announces Eight Abstracts Accepted for Presentation at the 2026 ASCO Gastrointestinal Cancers Symposium (Business Wire)
Jan-07-26 07:33AM	TEM's Stable Solvency and Financial Strength Are Gaining Attention (Zacks)
Jan-06-26 08:30AM	Tempus to Present at 44th Annual J.P. Morgan Healthcare Conference (Business Wire) +7.48%
Jan-05-26 12:43PM	Hims & Hers Expands Data-Driven, AI-Enabled Care and Personalization (Zacks)
Jan-02-26 09:10AM	TD Cowen Reaffirms Hold Rating on Tempus AI (TEM), Cites the Company's Position to be a Leader (Insider Monkey) +5.61%
Dec-30-25 11:47PM	Canaccord Lowers Price Objective On Tempus AI, Inc. (TEM) (Insider Monkey)
07:32AM	How Tempus AI Is Building Scale While Near-Term Risks Persist (Zacks)
Dec-29-25 08:48AM	TEM vs. HIMS: Which Medical Info Systems Stock Offers Greater Upside (Zacks)
Dec-26-25 07:18AM	How Tempus AI Is Advancing Toward Regulatory Pricing Catch-Up (Zacks)
Dec-22-25 10:19PM	BofA and JPMorgan Lower Tempus AI, Inc. (TEM) Price Targets on Valuation Concerns (Insider Monkey)
09:53AM	JPMorgan Lowers Tempus AI (TEM) PT to $80, Maintains Neutral Rating (Insider Monkey)
Dec-19-25 07:36AM	Tempus AI Approaching Profitability Despite GAAP Losses (Zacks)
Dec-17-25 11:22AM	Tempus AI Turns Non-GAAP Profit on Surging Genomics and Data (Zacks) -5.13%
Dec-16-25 12:11PM	Hims & Hers Scales Technology-Driven Care as Profitability Evolves (Zacks)
10:40AM	Tempus AI price target lowered to $80 from $90 at BofA (TipRanks)
09:07AM	Tempus AI Revenue Jumps 85% as Pricing Catalysts Line Up (Zacks)
08:13AM	3 MedTech Stocks Poised to Gain in 2026 From the AI Boom (Zacks)
Dec-15-25 11:30AM	Tempus AI Near $75 Target? Valuation, Upside and Risks (Zacks)
Dec-11-25 07:10AM	Tempus AI's Strategic Push to Expand Beyond Oncology (Zacks)
Dec-10-25 07:37AM	Is TEM Stock a Buy, Hold, or Sell During Its Pivotal Transition? (Zacks)
Dec-09-25 11:17AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool)
10:19AM	Is Tempus AI Stock a Buy Now or a Hold After a Big 2025 Run? (Zacks)
08:30AM	Tempus Announces Ten Abstracts Accepted for Presentation at the 2025 San Antonio Breast Cancer Symposium (Business Wire)
Dec-08-25 02:08PM	5 Tech Stocks Insiders Are Selling (But Smart Investors Are Loading Up) (MarketBeat)
10:15AM	Tempus AI: Data Flywheel and MRD Expansion Reshape the Outlook (Zacks)
Dec-05-25 09:41AM	Tempus AI: Revenue Mix and 2026 Growth Outlook Explained (Zacks)
09:25AM	Is Tempus AI the Next Big Artificial Intelligence Stock to Buy? (Motley Fool)
08:44AM	Tempus AI Boosts Its Clinical AI Capabilities Through Strategic Moves (Zacks)
Dec-04-25 11:30AM	Why Is Tempus (TEM) Down 8.9% Since Last Earnings Report? (Zacks)
10:38AM	Tempus AI, Inc. (TEM): A Bull Case Theory (Insider Monkey)
Dec-01-25 05:28AM	Cathie Wood's Health Tech Bet: Why Analysts See Long-Term Upside in Tempus AI (TEM) (Insider Monkey)
Nov-28-25 03:18PM	Why Tempus AI Stock Soared This Week (Motley Fool)
Nov-25-25 12:28PM	Hims & Hers Expands Care Scope as Digital Health Platforms Evolve (Zacks)
07:46AM	Tempus AI's Data Business Is Expanding and Adding to Revenues: Here's How (Zacks)
Nov-24-25 07:53AM	TEM vs. BFLY: Which Stock Offers Greater Upside Amid Health Tech Boom? (Zacks) +8.21%
Nov-18-25 08:30AM	Tempus to Participate in the Piper Sandler 37th Annual Healthcare Conference (Business Wire)
Nov-17-25 08:55AM	How Did Tempus AI Power Its Move to Positive EBITDA in Q3? (Zacks)
Nov-15-25 09:00AM	Alphabets Secret Portfolio Just Bought These 2 Stocks. Should You Buy Too? (24/7 Wall St.)
Nov-14-25 12:03PM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool)
08:30AM	Tempus and IFLI Announce Study to Advance Follicular Lymphoma Research (Business Wire)
07:57AM	TEM Continues to Strengthen Its Genomics Leadership With New Products (Zacks)
Nov-11-25 07:29AM	Should You Buy, Hold or Sell TEM Stock Post Q3 Earnings Release? (Zacks)
Nov-09-25 10:00PM	Nancy Pelosi posted up a staggering 16,930% return on investment, beat the market by 581%: Here are her 5 biggest wins (Moneywise)
Nov-07-25 12:43PM	Hims & Hers Expands AI-Driven Personalized and Subscription-Based Care (Zacks)
10:15AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool)
Nov-06-25 01:22PM	Tempus AI: Volatility Equates to Opportunity in AI Leader (MarketBeat) -12.36%
Nov-05-25 11:01AM	TEM's Q3 Earnings & Revenues Beat, Stock Down in After-Market Hours (Zacks)
08:30AM	Tempus Announces Six Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer Annual Meeting 2025 (Business Wire)
05:25AM	3 Growth Stocks to Invest $1,000 in Right Now (Motley Fool)
12:07AM	Tempus AI Inc (TEM) Q3 2025 Earnings Call Highlights: Strong Genomics Growth and Strategic ... (GuruFocus.com)
Nov-04-25 06:30PM	Tempus (TEM) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
05:45PM	Tempus AI (TEM) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Tempus Reports Third Quarter 2025 Results (Business Wire)
06:01AM	Sex Dolls, Boycotts, Protests: Furor in France as Shein Opens Paris Store (The Wall Street Journal)
Nov-03-25 04:36PM	Sex Dolls, Boycotts, Protests: Furor in France as Shein Opens Paris Store (The Wall Street Journal)

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Epstein David R	Director	Feb 02 '26	Sale	59.41	370	21,982	26,051	Feb 04 04:30 PM
LEFKOFSKY ERIC P	CEO and Chairman	Jan 28 '26	Sale	65.56	166,250	10,899,207	8,941,533	Jan 30 04:15 PM
Eric Lefkofsky	Officer	Jan 28 '26	Proposed Sale	66.81	166,250	11,107,162		Jan 28 04:21 PM
Fukushima Ryan	Chief Operating Officer	Jan 05 '26	Sale	64.26	5,000	321,300	148,808	Jan 07 06:25 PM
Doudna Jennifer A	Director	Jan 02 '26	Sale	60.17	1,250	75,212	22,702	Jan 06 04:15 PM
LEFKOFSKY ERIC P	CEO and Chairman	Dec 18 '25	Sale	63.99	166,250	10,638,478	8,974,783	Dec 22 05:41 PM
Eric Lefkofsky	Officer	Dec 18 '25	Proposed Sale	64.61	166,250	10,741,413		Dec 18 04:39 PM
Phelps Erik	EVP & Chief Admin & Legal Off	Dec 16 '25	Sale	67.42	1,302	87,781	89,280	Dec 18 04:15 PM
ERIK PHELPS	Officer	Dec 16 '25	Proposed Sale	68.67	1,302	89,408		Dec 16 04:29 PM
Rogers James William	Chief Financial Officer	Dec 11 '25	Sale	73.20	19,966	1,461,479	111,250	Dec 12 04:30 PM
JAMES ROGERS	Officer	Dec 11 '25	Proposed Sale	75.07	19,966	1,498,848		Dec 11 04:23 PM
Frederick Wayne A.I.	Director	Dec 05 '25	Sale	77.23	3,675	283,820	24,836	Dec 09 04:15 PM
WAYNE FREDERICK	Director	Dec 05 '25	Proposed Sale	77.23	3,675	283,802		Dec 05 04:15 PM
Epstein David R	Director	Dec 01 '25	Sale	75.55	250	18,888	26,421	Dec 03 04:50 PM
Fukushima Ryan	Chief Operating Officer	Dec 01 '25	Sale	75.72	5,000	378,620	153,808	Dec 03 04:50 PM
Doudna Jennifer A	Director	Dec 01 '25	Sale	75.55	676	51,072	23,952	Dec 03 04:50 PM
LEFKOFSKY ERIC P	CEO and Chairman	Nov 24 '25	Sale	74.10	166,250	12,319,125	9,008,033	Nov 25 04:30 PM
Polovin Andrew	EVP and General Counsel	Nov 24 '25	Sale	75.00	12,874	965,550	107,590	Nov 25 04:30 PM
Eric Lefkofsky	Officer	Nov 20 '25	Proposed Sale	70.40	166,250	11,703,285		Nov 24 06:11 PM
ANDREW POLOVIN	Officer	Nov 24 '25	Proposed Sale	70.29	12,874	904,913		Nov 24 04:29 PM
LEFKOFSKY ERIC P	CEO and Chairman	Nov 20 '25	Sale	68.97	166,250	11,466,099	9,041,283	Nov 20 07:56 PM
LEFKOFSKY ERIC P	CEO and Chairman	Nov 18 '25	Sale	65.54	16,829	1,102,944	2,003,213	Nov 20 07:56 PM
Rogers James William	Chief Financial Officer	Nov 18 '25	Sale	65.54	7,257	475,611	131,216	Nov 20 07:05 PM
Polovin Andrew	EVP and General Counsel	Nov 19 '25	Sale	68.06	6,387	434,707	120,464	Nov 20 07:05 PM
Polovin Andrew	EVP and General Counsel	Nov 18 '25	Sale	65.54	5,205	341,126	126,851	Nov 20 07:05 PM
Phelps Erik	EVP & Chief Admin & Legal Off	Nov 18 '25	Sale	65.54	3,533	231,547	90,582	Nov 20 07:05 PM
Fukushima Ryan	Chief Operating Officer	Nov 18 '25	Sale	65.54	10,099	661,870	829,081	Nov 20 07:05 PM
Bartolucci Ryan M	Chief Accounting Officer	Nov 18 '25	Sale	65.54	1,834	120,197	44,061	Nov 20 07:05 PM
Eric Lefkofsky	Officer	Nov 20 '25	Proposed Sale	69.09	166,250	11,486,212		Nov 20 04:46 PM
ANDREW POLOVIN	Officer	Nov 19 '25	Proposed Sale	66.77	6,387	426,460		Nov 19 04:22 PM
Ryan M. Bartolucci	Officer	Nov 18 '25	Proposed Sale	66.39	1,834	121,759		Nov 18 07:09 PM
Ryan Fukushima	Officer	Nov 18 '25	Proposed Sale	66.39	10,099	670,473		Nov 18 07:08 PM
Eric Paul Lefkofsky	Officer	Nov 18 '25	Proposed Sale	66.39	16,829	1,117,277		Nov 18 07:07 PM
Andrew Polovin	Officer	Nov 18 '25	Proposed Sale	66.39	5,205	345,560		Nov 18 07:05 PM
James William Rogers	Officer	Nov 18 '25	Proposed Sale	66.39	7,257	481,792		Nov 18 07:04 PM
Erik Phelps	Officer	Nov 18 '25	Proposed Sale	66.39	3,533	234,556		Nov 18 07:03 PM
Doudna Jennifer A	Director	Nov 11 '25	Sale	71.45	1,926	137,613	24,628	Nov 13 04:15 PM
JENNIFER DOUDNA	Director	Nov 11 '25	Proposed Sale	71.78	3,852	276,497		Nov 12 07:03 AM
Fukushima Ryan	Chief Operating Officer	Nov 03 '25	Sale	89.03	5,000	445,160	125,000	Nov 05 04:15 PM
Epstein David R	Director	Nov 03 '25	Sale	90.00	370	33,300	26,671	Nov 05 04:15 PM
VANESSA L KUBO	Officer	Nov 03 '25	Proposed Sale	89.85	20,000	1,797,000		Nov 03 04:26 PM
DAVID R. EPSTEIN	Director	Nov 03 '25	Proposed Sale	89.85	990	88,952		Nov 03 04:25 PM
LEFKOFSKY ERIC P	CEO and Chairman	Oct 28 '25	Sale	89.11	332,500	29,629,006	9,074,532	Oct 30 04:31 PM
Eric Lefkofsky	Officer	Oct 28 '25	Proposed Sale	91.58	332,500	30,450,350		Oct 28 04:09 PM
Fukushima Ryan	Chief Operating Officer	Oct 06 '25	Sale	92.32	5,000	461,606	130,000	Oct 08 04:15 PM
LEFKOFSKY ERIC P	CEO and Chairman	Sep 25 '25	Sale	76.56	332,500	25,457,014	9,141,032	Sep 29 04:33 PM
Eric Lefkofsky	Officer	Sep 25 '25	Proposed Sale	84.13	332,500	27,973,225		Sep 25 07:04 PM
Fukushima Ryan	Chief Operating Officer	Sep 02 '25	Sale	75.80	10,000	758,028	135,000	Sep 04 04:15 PM
Epstein David R	Director	Sep 02 '25	Sale	73.64	250	18,410	27,041	Sep 04 04:15 PM
LEFKOFSKY ERIC P	CEO and Chairman	Aug 27 '25	Sale	74.10	332,500	24,637,581	9,207,533	Aug 29 05:13 PM
Leonsis Theodore	Director	Aug 26 '25	Sale	75.83	20,000	1,516,600	66,756	Aug 28 04:15 PM
Eric Lefkofsky	Officer	Aug 27 '25	Proposed Sale	75.90	332,500	25,236,750		Aug 27 04:19 PM
Leonsis Theodore	Director	Aug 26 '25	Proposed Sale	75.83	20,000	1,516,650		Aug 26 01:27 PM
Polovin Andrew	EVP and General Counsel	Aug 19 '25	Sale	74.65	5,398	402,982	132,056	Aug 21 04:15 PM
Phelps Erik	EVP & Chief Admin & Legal Off	Aug 19 '25	Sale	74.65	3,664	273,532	94,115	Aug 21 04:15 PM
LEFKOFSKY ERIC P	CEO and Chairman	Aug 19 '25	Sale	74.65	17,458	1,303,307	2,020,042	Aug 21 04:15 PM
Fukushima Ryan	Chief Operating Officer	Aug 19 '25	Sale	74.65	17,460	1,303,456	839,180	Aug 21 04:15 PM
Rogers James William	Chief Financial Officer	Aug 19 '25	Sale	74.65	7,528	561,994	138,473	Aug 21 04:15 PM
Bartolucci Ryan M	Chief Accounting Officer	Aug 19 '25	Sale	74.65	1,904	142,141	45,895	Aug 21 04:15 PM
Erik Phelps	Officer	Aug 19 '25	Proposed Sale	78.45	3,664	287,441		Aug 20 07:19 AM
Andrew Polovin	Officer	Aug 19 '25	Proposed Sale	78.45	5,398	423,473		Aug 20 07:17 AM
Ryan Fukushima	Officer	Aug 19 '25	Proposed Sale	78.45	17,460	1,369,737		Aug 20 07:15 AM
Eric Paul Lefkofsky	Officer	Aug 19 '25	Proposed Sale	78.45	17,458	1,369,580		Aug 20 07:14 AM
James William Rogers	Officer	Aug 19 '25	Proposed Sale	78.45	7,528	590,572		Aug 19 09:59 PM
Ryan M. Bartolucci	Officer	Aug 19 '25	Proposed Sale	78.45	1,904	149,369		Aug 19 09:56 PM
Leonsis Theodore	Director	Aug 13 '25	Proposed Sale	69.90	44,000	3,075,786		Aug 18 02:44 PM
Leonsis Theodore	Director	Aug 13 '25	Sale	69.90	44,000	3,075,600	86,756	Aug 15 09:21 PM
Epstein David R	Director	Aug 01 '25	Sale	55.16	370	20,409	27,291	Aug 05 04:15 PM
DAVID R. EPSTEIN	Director	Aug 01 '25	Proposed Sale	56.59	620	35,086		Aug 01 04:30 PM
LEFKOFSKY ERIC P	CEO and Chairman	Jul 28 '25	Sale	62.87	166,250	10,452,027	9,274,033	Jul 30 08:42 PM
Eric Lefkofsky	Officer	Jul 28 '25	Proposed Sale	64.49	166,250	10,721,462		Jul 28 04:13 PM
Fukushima Ryan	Chief Operating Officer	Jul 07 '25	Sale	60.00	5,000	300,000	145,000	Jul 09 04:15 PM
VANESSA L KUBO	Officer	Jul 07 '25	Proposed Sale	60.97	20,000	1,219,400		Jul 07 04:16 PM
Doudna Jennifer A	Director	Jul 01 '25	Sale	62.52	625	39,075	26,554	Jul 03 04:15 PM
LEFKOFSKY ERIC P	CEO and Chairman	Jun 17 '25	Sale	70.07	250,000	17,516,593	9,357,283	Jun 20 04:15 PM
LEFKOFSKY ERIC P	CEO and Chairman	Jun 18 '25	Sale	69.44	250,000	17,359,469	9,307,283	Jun 20 04:15 PM
Phelps Erik	EVP & Chief Admin & Legal Off	Jun 16 '25	Sale	72.56	51,317	3,723,634	97,779	Jun 18 04:15 PM
Polovin Andrew	EVP and General Counsel	Jun 16 '25	Sale	72.13	1,423	102,641	137,454	Jun 18 04:15 PM
Eric Paul Lefkofsky	Officer	Jun 17 '25	Proposed Sale	72.00	400,000	28,800,000		Jun 17 09:45 PM
ERIK PHELPS	Officer	Jun 16 '25	Proposed Sale	71.28	51,317	3,657,876		Jun 16 04:30 PM
ANDREW POLOVIN	Officer	Jun 16 '25	Proposed Sale	71.28	1,423	101,431		Jun 16 04:22 PM
Leonsis Theodore	Director	Jun 11 '25	Sale	67.66	205,847	13,927,976	0	Jun 13 04:15 PM
Revolution Growth Management C	Shareholder	Jun 11 '25	Proposed Sale	69.38	205,847	14,281,665		Jun 11 04:02 PM
Fukushima Ryan	Chief Operating Officer	Jun 03 '25	Sale	62.29	20,000	1,245,764	856,640	Jun 05 04:15 PM
Doudna Jennifer A	Director	Jun 02 '25	Sale	55.20	558	30,802	27,179	Jun 04 04:15 PM
Epstein David R	Director	Jun 02 '25	Sale	55.20	250	13,800	27,661	Jun 04 04:15 PM
JENNIFER A DOUDNA	Director	Jun 02 '25	Proposed Sale	55.18	1,183	65,278		Jun 02 04:32 PM
Rogers James William	Chief Financial Officer	May 20 '25	Sale	63.27	23,121	1,462,809	146,001	May 22 08:00 PM
Polovin Andrew	EVP and General Counsel	May 20 '25	Sale	63.43	17,552	1,113,385	138,877	May 22 08:00 PM
Phelps Erik	EVP & Chief Admin & Legal Off	May 20 '25	Sale	63.21	8,415	531,918	149,096	May 22 08:00 PM
LEFKOFSKY ERIC P	CEO and Chairman	May 20 '25	Sale	63.21	16,752	1,058,905	4,878,837	May 22 08:00 PM
Fukushima Ryan	Chief Operating Officer	May 20 '25	Sale	63.21	7,820	494,308	876,640	May 22 08:00 PM
Bartolucci Ryan M	Chief Accounting Officer	May 20 '25	Sale	63.23	6,073	384,023	47,799	May 22 08:00 PM
Ryan M. Bartolucci	Officer	May 20 '25	Proposed Sale	63.74	4,254	271,150		May 21 07:39 PM
Ryan Fukushima	Officer	May 20 '25	Proposed Sale	63.74	7,820	498,447		May 21 07:36 PM
Andrew Polovin	Officer	May 20 '25	Proposed Sale	63.74	9,797	624,461		May 21 07:25 PM
Eric Paul Lefkofsky	Officer	May 20 '25	Proposed Sale	63.74	16,752	1,067,772		May 21 07:23 PM
Erik Phelps	Officer	May 20 '25	Proposed Sale	63.74	8,415	536,372		May 21 07:20 PM
James William Rogers	Officer	May 20 '25	Proposed Sale	63.74	11,413	727,465		May 21 07:18 PM
RYAN BARTOLUCCI	Officer	May 20 '25	Proposed Sale	63.74	1,819	115,943		May 20 04:32 PM

Open in Screener

PFE

Pfizer Inc

Feb 11 • 04:00PM ET

27.73

+0.12 0.43 %

Healthcare • Drug Manufacturers - General • USA • NYSE

Peers: BMY MRK SNY AMGN ABBV NVS JNJ GSK LLY AZN-D

| Held by: VTI VOO IVV SPY VTV XLV VYM DVY VHT FDL

Index	S&P 500	P/E	20.46	EPS (ttm)	1.36	Insider Own	0.09%	Shs Outstand	5.69B	Perf Week	3.55%
Market Cap	157.66B	Forward P/E	9.83	EPS next Y	2.82	Insider Trans	0.00%	Shs Float	5.68B	Perf Month	9.73%
Enterprise Value	204.69B	PEG	-	EPS next Q	0.72	Inst Own	67.18%	Short Float	2.52%	Perf Quarter	13.69%
Income	7.75B	P/S	2.52	EPS this Y	-7.74%	Inst Trans	0.16%	Short Ratio	2.59	Perf Half Y	12.49%
Sales	62.58B	P/B	1.70	EPS next Y	-5.06%	ROA	4.58%	Short Interest	143.04M	Perf YTD	11.37%
Book/sh	16.32	P/C	10.52	EPS next 5Y	-8.61%	ROE	10.59%	52W High	27.73 0.00%	Perf Year	8.62%
Cash/sh	2.64	P/FCF	15.20	EPS past 3/5Y	-37.12% -3.51%	ROIC	5.16%	52W Low	20.92 32.58%	Perf 3Y	-36.80%
Dividend Est.	1.76 (6.33%)	EV/EBITDA	7.83	Sales past 3/5Y	-14.56% 8.48%	Gross Margin	76.10%	Volatility	2.56% 2.26%	Perf 5Y	-19.46%
Dividend TTM	1.72 (6.20%)	EV/Sales	3.27	EPS Y/Y TTM	-3.74%	Oper. Margin	27.83%	ATR (14)	0.65	Perf 10Y	0.45%
Dividend Ex-Date	Jan 23, 2026	Quick Ratio	0.97	Sales Y/Y TTM	-1.65%	Profit Margin	12.38%	RSI (14)	64.96	Recom	2.39
Dividend Gr. 3/5Y	2.23% 2.37%	Current Ratio	1.28	EPS Q/Q	-509.90%	SMA20	5.36%	Beta	0.44	Target Price	28.57
Payout	126.47%	Debt/Eq	0.66	Sales Q/Q	-1.16%	SMA50	7.71%	Rel Volume	0.75	Prev Close	27.61
Employees	81000	LT Debt/Eq	0.62	Earnings	Feb 03 BMO	SMA200	11.82%	Avg Volume	55.28M	Price	27.73
IPO	Jan 17, 1944	Option/Short	Yes / Yes	EPS/Sales Surpr.	16.42% 4.20%	Trades		Volume	41,566,498	Change	0.43%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-07-26	Resumed	UBS	Neutral	$25
Dec-02-25	Resumed	Citigroup	Neutral	$26
Nov-13-25	Initiated	Scotiabank	Sector Outperform	$30
Apr-22-25	Initiated	Cantor Fitzgerald	Neutral	$24
Dec-10-24	Resumed	BofA Securities	Neutral	$29
Nov-15-24	Initiated	Wolfe Research	Underperform	$25
Oct-25-24	Resumed	Citigroup	Neutral	$30
Oct-17-24	Initiated	Bernstein	Mkt Perform	$32
Aug-07-24	Upgrade	Daiwa Securities	Neutral → Outperform
Mar-22-24	Downgrade	Argus	Buy → Hold
Feb-23-24	Initiated	Guggenheim	Buy	$36
Jan-04-24	Downgrade	TD Cowen	Outperform → Market Perform	$32
Oct-20-23	Resumed	UBS	Neutral	$36 → $34
Oct-16-23	Upgrade	Jefferies	Hold → Buy	$38 → $39
Jul-17-23	Reiterated	JP Morgan	Neutral	$45 → $41
Jul-14-23	Initiated	HSBC Securities	Buy	$50
Jun-29-23	Downgrade	Credit Suisse	Outperform → Neutral	$47 → $40
May-11-23	Downgrade	Daiwa Securities	Outperform → Neutral	$38
Mar-06-23	Initiated	Jefferies	Hold	$43
Feb-07-23	Upgrade	Daiwa Securities	Neutral → Outperform	$51

Show Previous Ratings

Feb-11-26 01:30PM	Pfizer Reports Strong Earnings Outlook - Unusual Call Options Activity Shows Investors are Bullish (Barchart)
12:57PM	Pharma companies left out of Trump's drug-pricing deals look for way in (Reuters)
10:35AM	Pfizer (PFE) Closes 2025 on Solid Note, Returns $9.8B to Shareholders (Insider Monkey)
08:09AM	Can Pfizer's New & Acquired Drugs Offset Its Looming Patent Cliff? (Zacks)
08:01AM	CorMedix Banks on DefenCath Sales in Q4 as Melinta Adds Upside (Zacks)
04:51PM	Loading…
Feb-10-26 04:51PM	Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. (Barrons.com)
11:06AM	Will BMY's Legacy Portfolio Decline Weigh on Its 2026 Top Line? (Zacks)
09:00AM	Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
06:41AM	Pfizer Inc. (PFE) Announces FDA's Grant of Priority Review for HYMPAVZI (marstacimab) sBLA (Insider Monkey)
12:37AM	5 Revealing Analyst Questions From Pfizer's Q4 Earnings Call (StockStory)
Feb-09-26 10:29AM	BMY Up 7.6% Post Q4 Earnings: Should You Buy, Sell or Hold the Stock? (Zacks)
09:11AM	Should You Buy, Sell or Hold Pfizer Stock After a Lukewarm Q4? (Zacks)
Feb-07-26 08:00AM	Pfizer CEO discusses the company's GLP-1 weight-loss drug pipeline (Yahoo Finance Video)
Feb-06-26 05:13PM	TrumpRx Is Here. Most People Won't Benefit. (Barrons.com)
03:37PM	3 High-Yield Dividend Stocks Perfect For Retirees (24/7 Wall St.)
11:58AM	Loading…
11:58AM	TrumpRx launches to slash drug prices for cash-paying US patients (Pharmaceutical Technology)
11:06AM	Pfizer Bets Big on Obesity and Oncology With 2026 Pipeline Push (Zacks)
08:00AM	China Biotech Lights Up. U.S. Stocks Prepare For A New Powerhouse. (Investor's Business Daily)
07:45AM	5 High-Yield Stocks (6%-8%) Every Retiree Should Consider Now (24/7 Wall St.)
07:08AM	White Houses online service for drug sales debuts with limited impact on prices (BioPharma Dive)
06:45AM	FDA Grants Priority Review for HYMPAVZI (marstacimab) sBLA for the Treatment of Two Hemophilia A or B Patient Populations with Significant Medical Need (Business Wire)
12:13AM	Trump Says People Will 'Save A Lot Of Money And Be Healthy' With Launch Of TrumpRx Website - But Will It Actually Fill Prescriptions? (Benzinga)
Feb-05-26 09:17PM	Trump launches TrumpRX website offering discounted prescription drugs (Investing.com)
08:06PM	Adaptive Biotechnologies Q4 Earnings Call Highlights (MarketBeat)
07:09PM	Pfizer Launches Cost Savings Program on TrumpRx Lowering Drug Costs for Millions of Americans (Business Wire)
05:22PM	Pfizer Pops on Q4 Results-But This May Be the Catalyst That Matters Most (MarketBeat)
04:17PM	TrumpRx's launch is hours away. Here's why it may not lower drug prices for most Americans. (MarketWatch)
01:29PM	Bristol Myers Earnings Reveal Struggling Legacy Drug Business. Why the Stock Is Rising. (Barrons.com)
10:49AM	Bristol-Myers Stock Up as Q4 Earnings and Revenues Beat Estimates (Zacks)
09:55AM	This Medical Technology Leader Sees Growth Into The 2040s (Investor's Business Daily)
08:21AM	Loading…
08:21AM	The Week Ahead: Inflation Data Hits Amid Earnings Season (Schaeffer's Research)
07:58AM	Rapid Innovation is Reshaping Oncology: Stocks in Focus (Zacks)
03:00AM	Big Pharma CEOs set sights on massive growth in years to come (Pharma Voice)
Feb-04-26 09:35PM	Pfizer Inc. (PFE): A Bull Case Theory (Insider Monkey)
01:11PM	Pfizer (PFE) Announces Positive Phase 2b Results for Obesity Drug Showing 12.30% Weight Loss (Insider Monkey)
11:40AM	Eli Lilly Soared by 39% in 2025, but Here's Another Healthcare Stock to Buy in 2026 (Motley Fool)
08:45AM	Novo Nordisk: Pfizer weight loss drug offers credible new competition (Proactive)
04:51AM	Earnings roundup: Amgen vs. FDA, Pfizers defense and Mercks $70B-in-sales plan (BioPharma Dive)
01:08AM	Pfizer Q4 Earnings Call Highlights (MarketBeat)
12:32AM	PFE Q4 CY2025 Deep Dive: Obesity Pipeline and Cost Discipline Face Post-COVID Headwinds (StockStory)
Feb-03-26 11:35PM	Will the Market Crash in 2026? Here's What History Says and What to Do About It (Motley Fool)
11:09PM	Asian shares gained and gold and silver climb higher after a retreat on Wall St (Associated Press Finance)
09:49PM	Why 2026 Could Be the Year Pfizer's Stock Finally Takes Off (Motley Fool)
06:03PM	Stocks to Watch Tuesday Recap: PayPal, PepsiCo, AMD, Disney (The Wall Street Journal)
04:36PM	These Stocks Are Todays Movers: Palantir, Pfizer, AMD, PayPal, Novo Nordisk, PepsiCo, Merck, and More (Barrons.com)
04:26PM	Stocks Tumble on AI Disruption Fears (Barchart)
04:09PM	Pfizer Dives; Why Lilly's Zepbound Still Looks Like The Weight-Loss Heavyweight (Investor's Business Daily)
04:03PM	Pfizer Inc (PFE) Q4 2025 Earnings Call Highlights: Strategic Acquisitions and Revenue Guidance ... (GuruFocus.com)
03:14PM	Analyst Report: Pfizer Inc. (Morningstar Research)
03:05PM	Stocks to Watch Tuesday: PayPal, PepsiCo, AMD, Disney (The Wall Street Journal)
02:57PM	These Are The Worst 25 Stocks to Own in February (Schaeffer's Research)
02:48PM	Obesity Drug Bets Get a Reality Checkbut Investors Shouldnt Panic (The Wall Street Journal)
02:24PM	Stock market today: Dow, Nasdaq, S&P 500 sink as tech falters amid flood of earnings (Yahoo Finance)
02:06PM	Pfizer is at 'the end of the beginning' in entry to GLP-1s: CEO (Yahoo Finance Video)
01:59PM	Pfizer sets sights on R&D strategy amid modest FY25 results (Pharmaceutical Technology)
12:33PM	Stock market today: Nasdaq, S&P 500 slide as investors digest flood of tech earnings, government shutdown (Yahoo Finance)
12:33PM	Stock market today: Dow, Nasdaq, S&P 500 fall as investors digest flood of tech earnings, government shutdown (Yahoo Finance)
12:22PM	Pfizer Releases Early Obesity Data Showing Up to 12.3% Weight Loss (GuruFocus.com)
11:40AM	Pfizer, Merk report Q4 results: Citi's Geoff Meacham on key takeaways (CNBC TV)
11:36AM	Why Pfizer Stock Dropped Today (Motley Fool)
11:32AM	Pfizer Stock Slides Despite Q4 Earnings Beat and New Obesity Drug Data (Zacks)
11:30AM	Why Is Pfizer Stock Sliding Today (GuruFocus.com)
11:04AM	2 Pharma Stocks React to Quarterly Results, Guidance (Schaeffer's Research)
11:00AM	Market Awaits JOLTS Jobs Report (Zacks)
10:48AM	Pfizer shares drop on quarterly loss (AFP)
10:40AM	Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook (CNBC TV)
10:35AM	Pfizer Projects Revenue Dip in 2026 as Patent Losses Weigh (GuruFocus.com)
10:32AM	Pfizer Stock Drops On Obesity-Drug Study Data (The Wall Street Journal)
10:26AM	Q4 Earnings, JOLTS & a Changing of the Disney Guard (Zacks)
09:59AM	Pfizer Targets Monthly Obesity Shot. Why Lilly Could Still Have The Weight-Loss Heavyweight. (Investor's Business Daily)
09:36AM	Stock market today: Nasdaq, S&P 500 fall as investors digest flood of tech earnings, partial government shutdown (Yahoo Finance)
09:36AM	Stock market today: Dow, S&P 500, Nasdaq edge higher as Palantir lifts tech hopes, earnings flood in (Yahoo Finance)
09:30AM	Pfizer (PFE) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
09:02AM	S&P 500, Nasdaq poised for higher open as earnings deluge takes center stage (Reuters)
08:50AM	Pfizer's Newly Acquired Drug Shows Weight Loss Of Just Around 13%, Stock Drops (Benzinga)
08:19AM	Pharma stocks slump as Pfizer and Merck report earnings (Quartz)
08:19AM	Merck and Pfizer decline vs the broader market as results released (Quartz)
07:55AM	Pfizer (PFE) Q4 Earnings and Revenues Beat Estimates (Zacks)
07:38AM	Pfizer Reaffirms FY26 Outlook As Q4 Results Top Estimates - Update (RTT News)
07:28AM	Pfizer says once-a-month weight-loss drug works as it forecasts profit decline (MarketWatch)
07:24AM	Jim Cramer Expresses Concern About Pfizer Despite Its "Terrific Yield" (Insider Monkey)
07:21AM	Pfizer Sales Fall on Continued Lower Covid-19 Drug Demand (The Wall Street Journal)
07:19AM	Pfizer (NYSE:PFE) Posts Better-Than-Expected Sales In Q4 CY2025 (StockStory)
07:02AM	Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. (Barrons.com)
06:53AM	Pfizer: Q4 Earnings Snapshot (Associated Press Finance)
06:45AM	Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance (Business Wire)
06:40AM	Pfizer's Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial (Business Wire)
05:25AM	These Stocks Are Moving the Most Today: Palantir, Teradyne, Tesla, AMD, NXP Semiconductors, and More (Barrons.com)
05:12AM	Goldman Sachs Maintains Neutral on Pfizer (PFE) Amid Rising Margin Pressure (Insider Monkey)
05:00AM	Advanced Micro Devices heads earnings slate (MarketWatch)
04:19AM	Stock Market Today: S&P 500 eyes fresh record as Dow and Nasdaq also called higher; Palantir rises after earnings; gold and silver rebound; AMD results on tap. (MarketWatch)
03:01AM	Big Tech and Pharma Earnings: What to Watch This Week (The Wall Street Journal)
Feb-02-26 07:00PM	AMD earnings, Netflix-Warner Bros. hearing: What to Watch (Yahoo Finance Video)
06:02PM	Big Tech and Pharma Earnings: What to Watch This Week (The Wall Street Journal)
02:08PM	Is Novo Nordisk Stock a Bargain Right Now? (Motley Fool)
01:59PM	Sanofi Found In Breach Of UK Pharmaceutical Marketing Code Over Beyfortus Claims (Benzinga)
11:12AM	Market Awaits January Manufacturing Numbers (Zacks)
10:35AM	Six More Weeks of Q4 Earnings Season? (Zacks)
10:25AM	What's in Store for These 5 Pharma Bigwigs This Earnings Season? (Zacks)
08:29AM	Palantir, AMD, Amazon and More Stocks with Earnings This Week (Benzinga)

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dolsten Mikael	Former Officer	May 23 '25	Proposed Sale	23.09	59,781	1,380,632		May 23 10:54 AM
Dolsten Mikael	Former Officer	May 05 '25	Proposed Sale	23.87	55,000	1,312,736		May 05 04:45 PM
DAMICO JENNIFER B.	SVP & Controller	Mar 04 '25	Sale	25.93	2,500	64,825	11,850	Mar 06 01:57 PM
DAMICO JENNIFER B.	SVP & Controller	Feb 27 '25	Option Exercise	31.31	22,416	701,845	31,063	Mar 03 05:39 PM
SUSMAN SALLY	Executive Vice President	Feb 27 '25	Option Exercise	31.31	85,182	2,667,048	250,866	Mar 03 05:38 PM
SAHNI PAYAL	Executive Vice President	Feb 27 '25	Option Exercise	31.31	19,054	596,581	44,242	Mar 03 05:38 PM
McDermott Michael	Executive Vice President	Feb 27 '25	Option Exercise	31.31	48,419	1,515,999	122,413	Mar 03 05:37 PM
LANKLER DOUGLAS M	Executive Vice President	Feb 27 '25	Option Exercise	31.31	156,914	4,912,977	309,790	Mar 03 05:37 PM
Fonseca Lidia	Executive Vice President	Feb 27 '25	Option Exercise	31.31	72,629	2,274,014	111,534	Mar 03 05:36 PM
BOURLA ALBERT	Chairman & CEO	Feb 27 '25	Option Exercise	31.31	582,823	18,248,188	931,744	Mar 03 05:36 PM
McDermott Michael	Executive Vice President	Feb 22 '25	Option Exercise	30.17	11,125	335,641	87,636	Feb 25 07:38 PM
DAMICO JENNIFER B.	SVP & Controller	Feb 22 '25	Option Exercise	30.17	8,741	263,716	17,602	Feb 25 07:38 PM
BOURLA ALBERT	Chairman & CEO	Feb 22 '25	Option Exercise	30.17	238,399	7,192,498	570,436	Feb 25 07:06 PM
LANKLER DOUGLAS M	Executive Vice President	Feb 22 '25	Option Exercise	30.17	85,824	2,589,310	232,775	Feb 25 07:05 PM
SAHNI PAYAL	Executive Vice President	Feb 22 '25	Option Exercise	30.17	12,714	383,581	37,099	Feb 25 07:04 PM
SUSMAN SALLY	Executive Vice President	Feb 22 '25	Option Exercise	30.17	63,573	1,917,997	225,184	Feb 25 07:02 PM
BOSHOFF CHRISTOFFEL	President, R&D	Feb 22 '25	Option Exercise	30.17	8,741	263,716	159,085	Feb 25 06:58 PM
BLAYLOCK RONALD E	Director	Feb 13 '25	Buy	25.65	19,457	499,072	27,707	Feb 14 05:16 PM

ILMN

Illumina Inc

TEM

Tempus AI Inc

PFE

Pfizer Inc

Upgrade your FINVIZ experience